利伐沙班预防血栓后综合征的系统评价与荟萃分析
该研究系统检索并汇总了8项研究共59,199例急性深静脉血栓患者,比较利伐沙班与华法林对血栓后综合征(PTS)的预防效果。结果显示利伐沙班组PTS发生率显著降低(OR 0.52),严重PTS及残余静脉血栓也更少,但静脉血栓栓塞复发风险的降低无统计学意义。
要点
- 利伐沙班较华法林显著降低PTS发生风险(OR 0.52,95%CI 0.43-0.63,P<.001)。
- 利伐沙班组严重PTS比例更低(3.7% vs 6.4%,OR 0.55,P=.024)。
- 利伐沙班与残余静脉血栓减少相关(36.5% vs 51.8%,P=.037)。
核心结论
- 急性深静脉血栓后使用利伐沙班较华法林与PTS风险降低相关。
- 利伐沙班组严重PTS和复发性静脉血栓栓塞事件更少见。
研究设计与样本
- 系统评价与荟萃分析,纳入6项回顾性研究和2项随机对照研究,共59,199例患者。
- 所有研究中利伐沙班均与初始低分子肝素后华法林方案进行比较。
- 59,199例中19,840例(33.5%)接受利伐沙班,39,377例(66.5%)接受华法林。
主要发现
- 利伐沙班组PTS发生率较华法林组显著降低(OR 0.52,95%CI 0.43-0.63,P<.001)。
- 严重PTS在利伐沙班组更少见(3.7% vs 6.4%,OR 0.55,95%CI 0.36-0.85,P=.024)。
- 利伐沙班与静脉血栓栓塞复发减少相关(OR 0.83,95%CI 0.59-1.18,P=.03)。
- 利伐沙班组残余静脉血栓比例低于华法林组(36.5% vs 51.8%,P=.037)。
关键数值与推荐
- PTS风险降低:OR 0.52,95%CI 0.43-0.63,P<.001。
- 严重PTS:利伐沙班3.7% vs 华法林6.4%,OR 0.55,95%CI 0.36-0.85,P=.024。
- 静脉血栓栓塞复发:OR 0.83,95%CI 0.59-1.18,P=.03。
- 残余静脉血栓:利伐沙班36.5% vs 华法林51.8%,P=.037。
临床怎么用
- 对于急性深静脉血栓患者,选择利伐沙班可能有助于降低PTS风险。
- 利伐沙班可能减少严重PTS和残余静脉血栓的发生。
- 需结合患者个体情况权衡抗凝方案对PTS的预防作用。
局限性
- 纳入研究以回顾性研究为主,仅2项随机对照研究,可能存在偏倚。
- 所有研究仅比较利伐沙班与华法林,结论不能外推至其他DOACs。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Direct oral anticoagulants (DOACs) have been recommended for the treatment of deep vein thrombosis (DVT). However, the benefits are uncertain for the prevention of post-thrombotic syndrome (PTS). We performed a systematic review and meta-analysis of reported studies to assess the efficacy of DOACs vs vitamin K antagonists for the risk reduction of PTS in patients with DVT. METHODS: We searched PubMed, Medline, the Cochrane Library, Embase, and the Web of Science for studies reporting on the development of PTS after acute DVT. The outcomes were the risk reduction of PTS, PTS severity, the presence of residual vein thrombosis, and the incidence of recurrent venous thromboembolic (VTE) events. RESULTS: A total of 59,199 patients from six retrospective and two randomized controlled studies had received DOAC treatment and were followed up for the development of PTS. In all studies, rivaroxaban had been compared with initial low-molecular-weight heparin followed by warfarin. Of the 59,199 patients, 19,840 (33.5%) had received rivaroxaban and 39,377 (66.5%), warfarin. The rivaroxaban group had a significant reduction in PTS development compared with the warfarin group (odds ratio [OR], 0.52; 95% confidence interval [CI], 0.43-0.63; P < .001). Severe PTS was less common in the rivaroxaban group than in the warfarin group (3.7% vs 6.4%; OR, 0.55; 95% CI, 0.36-0.85; P = .024). Additionally, rivaroxaban was associated with a significant reduction in VTE recurrence (OR, 0.83; 95% CI, 0.59-1.18; P = .03) and low rates of residual vein thrombosis compared with warfarin (36.5% vs 51.8%; P = .037). CONCLUSIONS: Rivaroxaban after acute DVT was associated with a reduced risk of PTS compared with warfarin. Patients treated with rivaroxaban more rarely developed severe PTS and recurrent VTE events compared with patients treated with warfarin.
引用
- Karathanos C, Nana P, Spanos K, et al. Efficacy of rivaroxaban in prevention of post-thrombotic syndrome: A systematic review and meta-analysis. J Vasc Surg Venous Lymphat Disord. 2021. PMID: 33965611. doi:10.1016/j.jvsv.2021.04.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。